We are live on ! Find out more
EDIT icon

Editas Medicine
EDIT

225 hedge funds and large institutions have $609M invested in Editas Medicine in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 53 increasing their positions, 74 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $9.68M

27% more capital invested

Capital invested by funds: $481M → $609M (+$128M)

15% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 34

2% more funds holding

Funds holding: 220 → 225 (+5)

1.21% less ownership

Funds ownership: 74.77% → 73.56% (-1.2%)

28% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 74

Holders
225
Holders Change
+5
Holders Change %
+2.27%
% of All Funds
3.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
39
Increased
53
Reduced
74
Closed
34
Calls
$13.5M
Puts
$9.68M
Net Calls
+$3.87M
Net Calls Change
+$1.26M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$10.5M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$6.06M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.07M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
+$4.88M
5
Citadel Advisors
Citadel Advisors
Florida
+$4.7M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$20.8M
2
DTC
Deep Track Capital
Connecticut
-$14.3M
3
Marshall Wace
Marshall Wace
United Kingdom
-$9.51M
4
State Street
State Street
Massachusetts
-$6.16M
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$2.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
201
Advisornet Financial
Minnesota
$962 – – –
HI
202
Harbour Investments
Wisconsin
$942 -$2.15K -245 -72%
BHWM
203
Beaird Harris Wealth Management
Texas
$811 – – –
KFI
204
Key Financial Inc
Pennsylvania
$760 -$97 -11 -13%
IRC
205
Investors Research Corp
Georgia
$760 – – –
CFGS
206
Concourse Financial Group Securities
Alabama
$759 – – –
MBFW
207
Morton Brown Family Wealth
Pennsylvania
$658 +$571 +65 New
TC
208
Truvestments Capital
Florida
$618 – – –
CFFP
209
Center for Financial Planning
Michigan
$507 – – –
NRG
210
Nemes Rush Group
Michigan
$507 – – –
LA
211
LM Advisors
California
$507 +$439 +50 New
First Manhattan
212
First Manhattan
New York
$435 -$3.51K -400 -90%
CFD
213
Creative Financial Designs
Indiana
$405 – – –
NSIM
214
North Star Investment Management
Illinois
$385 – – –
CTA
215
Colonial Trust Advisors
South Carolina
$304 – – –
NC
216
NewSquare Capital
Pennsylvania
$304 – – –
CSC
217
Caldwell Sutter Capital
California
$284 +$246 +28 New
CA
218
Clearstead Advisors
Ohio
$254 -$219 -25 -50%
HIA
219
Harbor Investment Advisory
Maryland
$203 – – –
AFWM
220
Abich Financial Wealth Management
Virginia
$122 +$105 +12 New
FFA
221
Farther Finance Advisors
California
$111 +$97 +11 New
FP
222
Financial Perspectives
Minnesota
$61 – – –
SSB
223
Sandy Spring Bank
Maryland
$21 – – –
Northwestern Mutual Wealth Management
224
Northwestern Mutual Wealth Management
Wisconsin
$10 -$88 -10 -91%
PP
225
PDT Partners
New York
– -$1.22M -156,515 Closed
7 8
9
10 11

EDIT Hedge Fund Activity: Q4 2023 in Review

225 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2023, worth a combined $609M — up 27% from $481M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new EDIT positions and 34 closed out — a net gain of 5 holders — while 53 added to existing stakes and 74 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $10.5M. The largest seller was Woodline Partners, cutting an estimated $20.8M.

  • 225 institutional investors held Editas Medicine (EDIT) as of Q4 2023, up from 220 in Q3 2023.
  • Funds reported $609M of Editas Medicine stock for Q4 2023, up 27% quarter-over-quarter.
  • 39 funds opened new Editas Medicine positions in Q4 2023 and 34 closed out, a net change of +5 holders.
  • The largest Editas Medicine buyer in Q4 2023 was Morgan Stanley, an estimated $10.5M added.
  • The largest Editas Medicine seller in Q4 2023 was Woodline Partners, an estimated $20.8M sold.

Based on aggregated 13F filings for Q4 2023.